FR22C1027I1 - Formulations stabilisant et inhibant la précipitation de compositions immunogènes - Google Patents

Formulations stabilisant et inhibant la précipitation de compositions immunogènes

Info

Publication number
FR22C1027I1
FR22C1027I1 FR22C1027C FR22C1027C FR22C1027I1 FR 22C1027 I1 FR22C1027 I1 FR 22C1027I1 FR 22C1027 C FR22C1027 C FR 22C1027C FR 22C1027 C FR22C1027 C FR 22C1027C FR 22C1027 I1 FR22C1027 I1 FR 22C1027I1
Authority
FR
France
Prior art keywords
formulations
stabilizing
inhibiting
precipitation
immunogenic compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1027C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38441477&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR22C1027(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of FR22C1027I1 publication Critical patent/FR22C1027I1/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR22C1027C 2006-04-26 2022-06-09 Formulations stabilisant et inhibant la précipitation de compositions immunogènes Active FR22C1027I1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79526106P 2006-04-26 2006-04-26
EP07760907.1A EP2010219B1 (en) 2006-04-26 2007-04-19 Formulations which stabilize and inhibit precipitation of immunogenic compositions
PCT/US2007/066959 WO2007127665A2 (en) 2006-04-26 2007-04-19 Novel formulations which stabilize and inhibit precipitation of immunogenic compositions

Publications (1)

Publication Number Publication Date
FR22C1027I1 true FR22C1027I1 (fr) 2022-09-09

Family

ID=38441477

Family Applications (1)

Application Number Title Priority Date Filing Date
FR22C1027C Active FR22C1027I1 (fr) 2006-04-26 2022-06-09 Formulations stabilisant et inhibant la précipitation de compositions immunogènes

Country Status (30)

Country Link
US (3) US7935787B2 (sl)
EP (5) EP3517129A1 (sl)
JP (7) JP5612305B2 (sl)
KR (9) KR101514913B1 (sl)
CN (4) CN105879021B (sl)
AR (2) AR060665A1 (sl)
AU (1) AU2007243019B2 (sl)
BR (2) BR122020000285B1 (sl)
CA (3) CA2650056C (sl)
CL (1) CL2007001185A1 (sl)
CR (1) CR10405A (sl)
CY (2) CY1116966T1 (sl)
DK (4) DK2676679T4 (sl)
EA (2) EA023470B1 (sl)
ES (4) ES2557504T3 (sl)
FR (1) FR22C1027I1 (sl)
HK (3) HK1196546A1 (sl)
HR (3) HRP20151203T1 (sl)
HU (5) HUE055682T2 (sl)
IL (3) IL194753A (sl)
LT (2) LT2676679T (sl)
MX (3) MX2008013572A (sl)
PL (4) PL2676679T3 (sl)
PT (4) PT2679244T (sl)
RU (1) RU2482878C2 (sl)
SI (4) SI2676679T1 (sl)
TR (1) TR201902402T4 (sl)
TW (1) TW200806315A (sl)
WO (1) WO2007127665A2 (sl)
ZA (1) ZA200809167B (sl)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101293920B (zh) 1998-05-01 2012-07-18 诺华疫苗和诊断公司 脑膜炎奈瑟球菌抗原和组合物
CA2929348A1 (en) 1999-05-19 2000-11-30 Novartis Vaccines And Diagnostics S.R.L. Combination neisserial compositions
AU784203B2 (en) 1999-10-29 2006-02-23 Glaxosmithkline Biologicals S.A. Neisserial antigenic peptides
ES2391153T3 (es) 2000-02-28 2012-11-22 Novartis Vaccines And Diagnostics S.R.L. Expresión heteróloga de proteínas de Neisseria
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0419408D0 (en) * 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CA2708716A1 (en) * 2007-12-21 2009-07-02 Glaxosmithkline Biologicals S.A. Vaccines for malaria
AU2009215364B2 (en) 2008-02-21 2014-09-18 Glaxosmithkline Biologicals S.A. Meningococcal fHBP polypeptides
CA2756522C (en) 2009-03-24 2018-06-26 Novartis Ag Adjuvanting meningococcal factor h binding protein
WO2010109324A1 (en) * 2009-03-24 2010-09-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
WO2010125480A1 (en) 2009-04-30 2010-11-04 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
EP2575870B1 (en) * 2010-06-04 2016-12-07 Wyeth LLC Vaccine formulations
US8802603B2 (en) 2010-06-17 2014-08-12 Becton, Dickinson And Company Medical components having coated surfaces exhibiting low friction and low reactivity
AU2011268507B2 (en) 2010-06-25 2014-08-14 Novartis Ag Combinations of meningococcal factor H binding proteins
EP3246044B2 (en) * 2010-08-23 2024-04-10 Wyeth LLC Stable formulations of neisseria meningitidis rlp2086 antigens
ES2864635T3 (es) 2010-09-10 2021-10-14 Wyeth Llc Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
FR2966044B1 (fr) * 2010-10-18 2012-11-02 Sanofi Pasteur Procede de conditionnement d'un vaccin contenant un adjuvant d'aluminium
TWI606840B (zh) 2010-11-11 2017-12-01 艾伯維生物技術有限責任公司 具有增進高濃度之抗-ＴＮＦα抗體之液體調配物
KR20140005892A (ko) * 2010-12-10 2014-01-15 머크 샤프 앤드 돔 코포레이션 면역원성 조성물의 진탕-유도된 응집을 완화시키는 신규한 제제
EP2797624A1 (en) 2011-12-29 2014-11-05 Novartis AG Adjuvanted combinations of meningococcal factor h binding proteins
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY167723A (en) 2012-03-09 2018-09-21 Pfizer Neisseria meningitidis compositions and methods thereof
US10376573B2 (en) 2012-06-14 2019-08-13 Glaxosmithkline Biologicals Sa Vaccines for serogroup X meningococcus
ES2912082T3 (es) 2012-06-26 2022-05-24 Lg Electronics Inc Método de decodificación de vídeo, método de codificación de vídeo y medio de almacenamiento legible por decodificador que almacena información de video codificada
JOP20200175A1 (ar) * 2012-07-03 2017-06-16 Novartis Ag حقنة
ES2685894T3 (es) 2013-03-08 2018-10-15 Pfizer Inc. Polipéptidos de fusión inmunogénicos
WO2015033251A2 (en) 2013-09-08 2015-03-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2015059147A1 (en) * 2013-10-25 2015-04-30 Bayer Pharma Aktiengesellschaft A novel stable formulation
IL296681B2 (en) * 2014-01-21 2024-09-01 Pfizer Immunogenic preparations including conjugated capsular saccharide antigens and their uses
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
CA2988366C (en) * 2015-06-08 2021-12-07 Serum Institute Of India Private Ltd. Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof.
PE20240927A1 (es) * 2015-07-21 2024-04-30 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos
CN108367094B (zh) * 2015-12-10 2021-09-14 株式会社目立康 肽组合物
CA3033364A1 (en) 2016-09-02 2018-03-08 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
KR20190103256A (ko) 2016-12-30 2019-09-04 수트로박스, 인코포레이티드 비자연 아미노산을 갖는 폴리펩타이드-항원 접합체
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
CN106620681A (zh) * 2017-01-12 2017-05-10 南京佰泰克生物技术有限公司 一种细胞裂解液、试剂盒及在制备肿瘤全细胞抗原负载dc肿瘤疫苗中的应用
US11197921B2 (en) 2017-01-31 2021-12-14 Merck Sharp & Dohme Corp. Methods for making polysaccharide-protein conjugates
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
KR102650073B1 (ko) 2017-01-31 2024-03-20 머크 샤프 앤드 돔 엘엘씨 스트렙토코커스 뉴모니아 혈청형 19f 유래의 협막 다당류 단백질 접합체의 제조 방법
WO2018156468A1 (en) * 2017-02-24 2018-08-30 Merck Sharp & Dohme Corp. Pneumococcal conjugate vaccine formulations
EP3589314A4 (en) 2017-02-24 2021-04-21 Merck Sharp & Dohme Corp. INCREASED IMMUNOGENICITY OF STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE PROTEIN CONJUGATES
EP3585427A4 (en) * 2017-02-24 2020-12-30 Merck Sharp & Dohme Corp. METHODS FOR IMPROVING THE FILTRABILITY OF POLYSACCHARIDE CONJUGATE WITH PROTEIN REACTIONS
CA3074703A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
WO2019050816A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER
US20200325020A1 (en) * 2017-10-25 2020-10-15 Merck Sharp & Dohme Corp. Adjuvanted vaccines
CN117982633A (zh) 2017-12-06 2024-05-07 默沙东有限责任公司 包含肺炎链球菌多糖蛋白缀合物的组合物及其使用方法
WO2019212844A1 (en) 2018-04-30 2019-11-07 Merck Sharp & Dohme Corp. Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
EP3787673A4 (en) 2018-04-30 2022-04-27 Merck Sharp & Dohme Corp. METHODS FOR PRODUCING CAPSULAR CARRIER PROTEIN-POLYSACCHARIDE CONJUGATES OF STREPTOCOCCUS PNEUMONIAE
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
KR20210076016A (ko) * 2018-09-24 2021-06-23 바이오백시스 인크. 바이합텐화된 자가 백신 및 그의 용도
SG11202106541WA (en) 2018-12-19 2021-07-29 Merck Sharp & Dohme Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
US20240230545A9 (en) 2021-02-26 2024-07-11 Biological E Limited Activated-quenched polysaccharide and improved methods for quantification of polysaccharide in a vaccine composition

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1189340A (en) * 1967-09-13 1970-04-22 American Cyanamid Co Antigen-Adjuvant Composition
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
FR2630115B1 (fr) * 1988-04-14 1994-10-28 Merieux Inst Procede de stabilisation des solutions d'albumine humaine et solution obtenue
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
ES2082052T3 (es) * 1990-07-19 1996-03-16 Nardino Righi Jeringuilla de seguridad, de un solo uso.
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
WO1993013302A1 (de) 1991-12-23 1993-07-08 Michael Zoche Motor mit einer vorrichtung zur entölung
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
JP3755890B2 (ja) 1992-06-25 2006-03-15 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） アジュバント含有ワクチン組成物
EP0616034B1 (en) 1993-03-05 2004-10-20 Wyeth Holdings Corporation Plasmid for production of CRM protein and diphtheria toxin
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JP3696267B2 (ja) 1994-02-28 2005-09-14 天野エンザイム株式会社 生理活性蛋白質の安定化方法
DE4407489A1 (de) * 1994-03-07 1995-09-14 Bayer Ag Vakzine zur Prävention von Respirations- und Reproduktionserkrankungen des Schweines
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5846547A (en) 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US6355255B1 (en) 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
RU2098109C1 (ru) 1996-09-26 1997-12-10 Александр Григорьевич Чучалин Противоаллергическое, противовоспалительное средство, способ его получения, лечебное и косметическое средства с его использованием
US5932223A (en) 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations
US6403098B1 (en) 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
JP4078406B2 (ja) * 1997-01-22 2008-04-23 有限会社コーキ・エンジニアリング 注射器のシリンダの製造方法
CA2286294A1 (en) * 1997-04-08 1998-10-15 Merck & Co., Inc. Stabilized human papillomavirus formulations
US6113918A (en) * 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
US6224880B1 (en) * 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
CA2264970A1 (en) * 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
AU770333B2 (en) 1998-09-30 2004-02-19 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Mutant cholera holotoxin as an adjuvant
GB9909077D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
WO2000056360A2 (en) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Vaccine against antigens from bacteriae
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
ATE400296T1 (de) * 1999-12-02 2008-07-15 Novartis Vaccines & Diagnostic Zusammensetzungen und methoden zur stabilisierung von biologischen molekülen nach lyophilisierung
DE10012370A1 (de) * 2000-03-14 2001-09-27 Chiron Behring Gmbh & Co Adjuvans für Vakzinen
IL152959A0 (en) 2000-06-08 2003-06-24 Intercell Biomedizinische Forschungs & Entwicklungs Gmbh Immunostimulatory oligodeoxynucleotides
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
EP1946769B1 (en) * 2000-06-29 2012-05-30 SmithKline Beecham Biologicals S.A. Multivalent vaccine composition with reduced dose of Haemophilus influenzae type B
KR100385711B1 (ko) * 2000-07-05 2003-05-27 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드와 백일해균 및ｂ형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법
AU7193501A (en) * 2000-07-10 2002-01-21 Us Health Multiple antigenic peptides immunogenic against streptococcus pneumoniae
GB0025414D0 (en) * 2000-10-16 2000-11-29 Consejo Superior Investigacion Nanoparticles
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
CN1516595A (zh) * 2001-03-19 2004-07-28 Iomai公司 用于经皮免疫的贴剂
KR100877258B1 (ko) 2001-06-07 2009-01-12 와이어쓰 홀딩스 코포레이션 보조제로서 콜레라 홀로톡신의 돌연변이체 형태
JP2004535187A (ja) 2001-06-07 2004-11-25 ワイス・ホールデイングス・コーポレーシヨン アジュバントとしてのコレラホロトキシンの突然変異形
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
WO2003009869A1 (en) * 2001-07-26 2003-02-06 Chiron Srl. Vaccines comprising aluminium adjuvants and histidine
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
KR100913714B1 (ko) * 2001-11-08 2009-08-24 패시트 바이오테크 코포레이션 Ｉｇｇ 항체의 안정한 액상 약학 제형물
CA2512917A1 (en) 2003-01-15 2004-08-05 Wyeth Holdings Corporation Methods for increasing neisseria protein expression
EP2172213B1 (en) * 2003-01-30 2013-04-03 Novartis AG Injectable vaccines against multiple meningococcal serogroups
SI3417875T1 (sl) * 2003-02-10 2021-01-29 Biogen Ma Inc. Formulacija imunoglobulina in metode za njegovo pripravo
EP1603950A2 (en) 2003-03-17 2005-12-14 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
WO2004094596A2 (en) * 2003-04-16 2004-11-04 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
CA2528723A1 (en) * 2003-06-25 2005-01-06 Elan Pharmaceuticals, Inc. Methods and compositions for treating rheumatoid arthritis
UA67144A (en) 2003-07-29 2004-06-15 Inst Exprm & Clinical Veterina Method for production of inactivated vaccine against salmonellosis and escherichiosis of animals
BRPI0413309B8 (pt) 2003-08-06 2021-05-25 The Government Of The Us Secretary Department Of Health And Human Services método para a preparação de uma vacina conjugada de polissacarídeo-proteína
DE10348550A1 (de) * 2003-10-20 2005-06-16 Hexal Biotech Forschungsgmbh Stabile wässrige G-CSF-haltige Zusammensetzungen
RU37462U1 (ru) 2004-01-16 2004-04-27 Бычкова Ольга Владимировна Пробирка
CA2586058A1 (en) * 2004-11-01 2006-05-11 Dennis L. Kasper Modified streptococcal polysaccharides and uses thereof
SV2008002394A (es) * 2005-01-28 2008-02-08 Wyeth Corp Formulaciones liquidas estabilizadas de polipeptido ref. ahn- 072sv
IL308456A (en) * 2005-04-08 2024-01-01 Wyeth Llc A multivalent pneumomuroral protein-polysaccharide conjugate preparation
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
GB0524066D0 (en) * 2005-11-25 2006-01-04 Chiron Srl 741 ii
US20070253985A1 (en) 2006-04-26 2007-11-01 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
EP2589392B1 (en) 2008-03-05 2016-11-30 Sanofi Pasteur Process for stabilizing an adjuvant containing vaccine composition

Also Published As

Publication number Publication date
SI2679245T1 (sl) 2021-11-30
KR20090017537A (ko) 2009-02-18
TW200806315A (en) 2008-02-01
KR101514913B9 (en) 2022-06-24
WO2007127665A2 (en) 2007-11-08
KR20200032268A (ko) 2020-03-25
CN105879021A (zh) 2016-08-24
AU2007243019A1 (en) 2007-11-08
ZA200809167B (en) 2009-06-24
PL2010219T3 (pl) 2016-03-31
EA017436B1 (ru) 2012-12-28
KR20140132779A (ko) 2014-11-18
TR201902402T4 (tr) 2019-03-21
IL239978A0 (en) 2015-08-31
CR10405A (es) 2009-02-26
EA023470B1 (ru) 2016-06-30
CN103768615B (zh) 2016-06-01
DK2010219T3 (en) 2016-01-11
US20130034580A1 (en) 2013-02-07
PT2679245T (pt) 2021-09-02
BR122020000285B1 (pt) 2023-05-09
PL2679244T3 (pl) 2022-06-20
KR20210111326A (ko) 2021-09-10
CA2873346A1 (en) 2007-11-08
EP2676679A2 (en) 2013-12-25
US8562999B2 (en) 2013-10-22
JP2009535353A (ja) 2009-10-01
KR20140004258A (ko) 2014-01-10
HK1223569A1 (zh) 2017-08-04
CN101500612B (zh) 2013-12-25
EP2679245B1 (en) 2021-07-28
IL194753A (en) 2015-08-31
CA2803111C (en) 2015-06-16
DK2676679T4 (da) 2024-09-16
MX359741B (es) 2018-10-09
HK1209358A1 (en) 2016-04-01
JP2014055169A (ja) 2014-03-27
EP2010219A2 (en) 2009-01-07
HRP20151203T1 (hr) 2015-12-04
US7935787B2 (en) 2011-05-03
AU2007243019B2 (en) 2012-06-21
JP2018123145A (ja) 2018-08-09
CY1121251T1 (el) 2020-05-29
CL2007001185A1 (es) 2008-01-18
JP2014221806A (ja) 2014-11-27
CN103768615A (zh) 2014-05-07
SI2676679T1 (sl) 2019-03-29
US20070253984A1 (en) 2007-11-01
CN104857524A (zh) 2015-08-26
DK2676679T3 (en) 2019-03-04
US20110172393A1 (en) 2011-07-14
HUE028137T2 (hu) 2016-11-28
MX2008013572A (es) 2009-03-06
WO2007127665A3 (en) 2008-11-13
EA200870480A1 (ru) 2009-04-28
CA2873346C (en) 2017-09-05
HK1196546A1 (zh) 2014-12-19
HUE042923T2 (hu) 2019-07-29
HRP20190198T1 (hr) 2019-04-05
IL239788A0 (en) 2015-08-31
HUS2200028I1 (hu) 2022-07-28
HRP20211417T1 (hr) 2021-12-10
KR20160049063A (ko) 2016-05-04
HUE058394T2 (hu) 2022-08-28
DK2679244T3 (da) 2022-04-11
EP2676679A3 (en) 2014-01-01
EP2679244B1 (en) 2022-03-23
HUE055682T2 (hu) 2021-12-28
ES2885762T3 (es) 2021-12-15
EP3517129A1 (en) 2019-07-31
EP2679245A2 (en) 2014-01-01
KR101514847B1 (ko) 2015-04-24
CN105879021B (zh) 2020-11-24
KR101514913B1 (ko) 2015-04-23
PT2010219E (pt) 2016-01-29
EP2676679B2 (en) 2024-08-28
EP2679244A3 (en) 2014-01-15
PL2676679T3 (pl) 2019-06-28
SI2679244T1 (sl) 2022-05-31
KR20220061256A (ko) 2022-05-12
BRPI0710918B1 (pt) 2021-02-02
CA2803111A1 (en) 2007-11-08
PT2676679T (pt) 2019-03-01
AR110731A2 (es) 2019-04-24
RU2008141680A (ru) 2010-06-10
PL2679245T3 (pl) 2021-11-08
PT2679244T (pt) 2022-04-19
EP2676679B1 (en) 2019-01-02
EP2010219B1 (en) 2015-10-28
SI2010219T1 (sl) 2015-12-31
JP2021176910A (ja) 2021-11-11
MX2018012171A (es) 2021-12-08
BRPI0710918B8 (pt) 2021-05-25
ES2712956T3 (es) 2019-05-16
CN104857524B (zh) 2018-08-28
ES2557504T3 (es) 2016-01-26
JP6321094B2 (ja) 2018-05-09
CY1116966T1 (el) 2017-04-05
KR20170122857A (ko) 2017-11-06
EP2679245A3 (en) 2014-01-15
JP5612305B2 (ja) 2014-10-22
EA201200929A1 (ru) 2013-05-30
EP2679244A2 (en) 2014-01-01
CA2650056C (en) 2013-07-16
AR060665A1 (es) 2008-07-02
JP2019194240A (ja) 2019-11-07
CN101500612A (zh) 2009-08-05
KR102093269B1 (ko) 2020-04-23
LTPA2022509I1 (sl) 2022-06-27
DK2679245T3 (da) 2021-09-06
IL194753A0 (en) 2009-08-03
IL239978B (en) 2019-06-30
ES2910432T3 (es) 2022-05-12
JP6192115B2 (ja) 2017-09-06
KR20180130004A (ko) 2018-12-05
RU2482878C2 (ru) 2013-05-27
JP2016222701A (ja) 2016-12-28
CA2650056A1 (en) 2007-11-08
LT2676679T (lt) 2019-03-12
BRPI0710918A2 (pt) 2012-03-06

Similar Documents

Publication Publication Date Title
FR22C1027I1 (fr) Formulations stabilisant et inhibant la précipitation de compositions immunogènes
BRPI0913379A2 (pt) formulações farmacêuticas sólidas compreendendo bibw 2992
IL190885A0 (en) Immunogenic compositions and methods of use
IL195237A0 (en) Conjugates of aziridinyl-epothilone analogs and pharmaceutical compositions comprising same
BRPI1014854A2 (pt) "conjugados polímero-agente, partículas, composições, e métodos de uso relacionados"
HK1134679A1 (zh) 用於治療感染的組合物和方法
IL193074A0 (en) Stable pharmaceutical formulations of montelukast sodium
IL198513A0 (en) Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
ZA200903636B (en) Formulations of PEG-Interferon alpha conjugates
EP2076281A4 (en) STABILIZING ALKYLGLYCOSIDIC COMPOSITIONS AND METHODS THEREOF
ATE502682T1 (de) Zusammensetzung zur feuerbekämpfung und formulierungen aus dieser zusammensetzung
CY2022016I1 (el) Σκευασματα που σταθεροποιουν και αναστελλουν την καταβυθιση ανοσογονων συνθεσεων